U.S. Markets open in 3 hrs 44 mins
S&P Futures
2,497.00-4.00(-0.16%)Dow Futures
22,306.00-27.00(-0.12%)
| Previous Close | 152.95 |
| Open | 152.96 |
| Bid | 142.00 x 100 |
| Ask | 0.00 x 0 |
| Day's Range | 152.16 - 153.03 |
| 52 Week Range | 120.38 - 154.66 |
| Volume | 104,651 |
| Avg. Volume | 181,537 |
| Net Assets | 7.93B |
| NAV | 151.13 |
| PE Ratio (TTM) | 63.03 |
| Yield | 1.30% |
| YTD Return | 19.94% |
| Beta (3y) | 0.88 |
| Expense Ratio (net) | 0.10% |
| Inception Date | 2004-01-26 |
- Market Realist•4 days ago
Regeneron Is Focused on Advancing Development of Fasinumab for Chronic Pain
On September 20, 2016, Regeneron (REGN) entered into a partnership with Teva Pharmaceutical (TEVA) for the development and commercialization of Fasinumab in the US.
- Market Realist•7 days ago
What Analysts Recommend for Sage Therapeutics
Sage Therapeutics (SAGE) is a clinical-research-based biopharmaceutical company focused on developing drugs for life-threatening central nervous system disorders.
- Market Realist•14 days ago
Behind Merck’s Revenues in 2Q17
Analysts estimate a 0.1% decline in Merck's revenues to ~$10.5 billion in 3Q17.
